CADL — Candel Therapeutics, Inc. stock price, charts and financials

QT87Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (NASDAQ: CADL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
10.56
-0.03-0.32%
OverviewShort InterestFilings
CADLQT87Candel Therapeutics, Inc.·NASDAQ
10.56-0.32%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.45%$15.46MESO+4.71%$16.69ZBIO-0.83%$32.16GHRS-1.62%$29.78TSHA-1.51%$6.46STOK-1.22%$32.31ABCL+39.97%$9.70VRDN-3.29%$22.81
Snapshot
Index-P/E-EPS (ttm)-Insider Own10.33%Shs Outstand73.27MPerf Week5.79%
Market Cap775.93MForward P/E-EPS next Y-0.69Insider Trans6.87%Shs Float56.81MPerf Month7.08%
Enterprise Value582.89MPEG0.22EPS next Q-Inst Own-Short Float22.82%Perf Quarter35.94%
Income-63.94MP/S0.00EPS this Y-Inst Trans-Short Ratio6.11Perf Half Y100.19%
Sales0.00P/B4.78EPS next Y25.52%ROA-26.95%Short Interest12.96MPerf YTD87.43%
Book/sh-P/C-EPS next 5Y-ROE-60.42%52W High11.32 -6.78%Perf Year77.68%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-28.89%52W Low4.34 143.45%Perf 3Y880.56%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.36% 5.78%Perf 5Y39.53%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM43.68%Oper. Margin0.00%ATR (14)0.55Perf 10Y-
Dividend Ex-Date-Quick Ratio28.05Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.28Recom2.10
Dividend Gr. 3/5Y-Current Ratio28.05EPS Q/Q-207.69%SMA206.30%Beta-0.45Target Price22.50
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5012.54%Rel Volume0.43Prev Close10.59
Employees55LT Debt/Eq0.02EarningsAug 13SMA20059.07%Avg Volume1.84MPrice10.56
IPO DateJul 27, 2021Option/ShortYes / YesEPS/Sales Surpr.52.68% -Net Debt/EBITDA3.84Volume798,418Change-0.32%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-29-26ReiteratedH.C. WainwrightBuy$23
Jul-13-26InitiatedStifelBuy$22
Oct-27-25InitiatedStephensOverweight$15
Sep-03-25DowngradeB of A SecuritiesBuy → Neutral
Latest News
Aug-07-26
Aug-07-2611:08AM
Candel Therapeutics: Getting Closer, And Building Out More Pathsseekingalpha.com
Aug-03-26
Aug-03-2604:05PM
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
08:05AM
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026globenewswire.com
Jul-29-26
Jul-29-2608:05AM
Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Bostonglobenewswire.com
Jul-13-26
Jul-13-2605:53AM
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22Benzinga
Jul-08-26
Jul-08-2604:05PM
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-04-26
Jul-04-2602:06AM
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real PotentialSeekingAlpha
Jul-01-26
Jul-01-2604:05PM
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jun-30-26
Jun-30-2608:05AM
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitorsglobenewswire.com
Company

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other181414————
Research and Development301925————
Other Operating Expense00-1————
Operating Income-48-33-38————
Interest Expense223————
Unusual Expense
———————
Non-Operating Income (Expense)12-203————
Net Income Before Taxes-38-55-38————
Income Taxes
000————
Consolidated Net Income-38-55-38————
Net Income From Continuing Operations-38-55-38————
Net Income-38-55-38————
EPS (Recurring)-0.72-1.74-1.31————
EPS (Basic, Before Extraordinaries)-0.72-1.74-1.31————
EPS (Diluted)-0.72-1.74-1.31————
EBITDA-35-52-34————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding533229————
Market Capitalization29927843————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$11.52$9.51$7.50$5.50$3.49● Close Price0.00M0.75M1.50M2.25M3.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Barone FrancescaChief Scientific OfficerJun 29 '26Sale10.0623,447235,76977,362Jul 01
Tyagarajan SeshuChief Technology OfficerJun 29 '26Sale10.027,00070,15183,865Jul 01
Manning Paul BDirectorFeb 23 '26Buy5.45550,4582,999,9962,763,527Feb 26
Nichols William GarrettChief Medical OfficerJul 28 '25Option Exercise1.299371,20953,430Jul 30
Nichols William GarrettChief Medical OfficerJul 28 '25Sale6.989376,54052,493Jul 30
Nichols William GarrettChief Medical OfficerJun 30 '25Sale5.047813,93652,493Jul 02
Nichols William GarrettChief Medical OfficerJun 30 '25Option Exercise1.297811,00753,274Jul 02
Tak Paul PeterChief Executive OfficerMar 19 '25Sale9.004003,601225,740Mar 20
Nichols William GarrettChief Medical OfficerMar 18 '25Option Exercise1.9018,48935,12797,809Mar 20
Nichols William GarrettChief Medical OfficerMar 18 '25Sale8.7645,316396,99552,493Mar 20
Barone FrancescaChief Scientific OfficerMar 18 '25Option Exercise1.5518,00027,900128,673Mar 20
Barone FrancescaChief Scientific OfficerMar 18 '25Sale8.7632,146281,67396,527Mar 20
Tak Paul PeterChief Executive OfficerMar 18 '25Sale8.7725,772226,023226,140Mar 20
Tyagarajan SeshuChief Technology OfficerMar 17 '25Option Exercise1.2920,00025,800116,790Mar 20
Schoch CharlesSee RemarksMar 17 '25Sale8.835,00044,16938,038Mar 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.